Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 2
2013 1
2014 2
2015 3
2016 1
2017 5
2018 3
2019 3
2020 8
2021 10
2022 7
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, Weber MD, Lokku A, Smith LM, Foreman NK, Hajjar FM, McNall-Knapp RY, Weintraub L, Antony R, Franson AT, Meade J, Schiff D, Walbert T, Ambady P, Bota DA, Campen CJ, Kaur G, Klesse LJ, Maraka S, Moots PL, Nevel K, Bornhorst M, Aguilar-Bonilla A, Chagnon S, Dalvi N, Gupta P, Khatib Z, Metrock LK, Nghiemphu PL, Roberts RD, Robison NJ, Sadighi Z, Stapleton S, Babovic-Vuksanovic D, Gershon TR; ReNeu Trial Investigators; ReNeu Study Investigators. Moertel CL, et al. Among authors: ambady p. J Clin Oncol. 2024 Nov 8:JCO2401034. doi: 10.1200/JCO.24.01034. Online ahead of print. J Clin Oncol. 2024. PMID: 39514826
Comparison of dynamic susceptibility contrast (DSC) using gadolinium and iron-based contrast agents in high-grade glioma at high-field MRI.
Wongsawaeng D, Schwartz D, Li X, Muldoon LL, Stoller J, Stateler C, Holland S, Szidonya L, Rooney WD, Wyatt C, Ambady P, Fu R, Neuwelt EA, Barajas RF Jr. Wongsawaeng D, et al. Among authors: ambady p. Neuroradiol J. 2024 Aug;37(4):473-482. doi: 10.1177/19714009241242596. Epub 2024 Mar 27. Neuroradiol J. 2024. PMID: 38544404
Deciphering spatially distinct immune microenvironments in glioblastoma using ferumoxytol and gadolinium-enhanced and FLAIR hyperintense MRI phenotypes.
Stoller J, Kersch CN, Muldoon LL, Ambady P, Harrington CA, Fu R, Raslan AM, Dogan A, Neuwelt EA, Barajas RF Jr. Stoller J, et al. Among authors: ambady p. Neurooncol Adv. 2023 Nov 8;5(1):vdad148. doi: 10.1093/noajnl/vdad148. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 38077209 Free PMC article.
Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors.
Uluc K, Ambady P, McIntyre MK, Tabb JP, Kersch CN, Nerison CS, Huddleston A, Liu JJ, Dogan A, Priest RA, Fu R, Prola Netto J, Siler DA, Muldoon LL, Gahramanov S, Neuwelt EA. Uluc K, et al. Among authors: ambady p. Neurooncol Adv. 2022 Jun 25;4(1):vdac104. doi: 10.1093/noajnl/vdac104. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35892048 Free PMC article.
[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
Barajas RF Jr, Ambady P, Link J, Krohn KA, Raslan A, Mallak N, Woltjer R, Muldoon L, Neuwelt EA. Barajas RF Jr, et al. Among authors: ambady p. Neurooncol Pract. 2022 Mar 9;9(3):246-250. doi: 10.1093/nop/npac021. eCollection 2022 May. Neurooncol Pract. 2022. PMID: 35601969 Free PMC article.
43 results